Boji Medical approves 2024 financials and key management compensation

Boji Medical (SZSE:300404) successfully held its 2024 Annual General Meeting of Shareholders, where a comprehensive set of resolutions were passed. Key approvals included the 2024 Board of Directors and Supervisory Board work reports, the company's 2024 annual report and its summary, the 2024 financial statements, and a proposed profit distribution plan. The meeting also confirmed the compensation for directors and senior management in 2024 and set the compensation plan for 2025. Additionally, shareholders approved the reelection of directors, a proposal to provide guarantees for subsidiaries' business contracts, and the closing of a project and reallocation of capital. The company's 2025 auditing firm was reappointed, along with other resolutions. The meeting was conducted through a combination of on-site and online voting, with legal oversight from the firm, Kangda (Guangzhou) Lawyers.